. 2023 Oct 6;102(40):e35353. doi: 10.1097/MD.0000000000035353

Table 3.

Leukocyte count subgroup analysis.

Indicators	Number of included studies	SMD (95% CI)	Heterogeneity test		Effect model	P	Heterogeneity test
Indicators	Number of included studies	SMD (95% CI)	P	I²(%)	Effect model	P	P	I²(%)
Oncological diseases	9^{[44,48,49,58,61,66,68]}	1.18 (0.74, 1.62)	P < .00001	86	Random effects model	P < .00001	P = .20	38.4
Other diseases	4^{[42,47,54,55]}	0.86 (0.61, 1.10)	P = .79	0	Random effects model	P < .00001	P = .20	38.4
Hormone therapy group	5^{[38,39,59,61,66]}	0.98 (0.37, 1.59)	P < .00001	89	Random effects model	P = .002	P = .64	0
Non-hormonal therapy group	8^{[42,44,47,49,54,55,58,68]}	1.15 (0.81, 1.48)	P = .002	69	Random effects model	P < .00001	P = .64	0
≤2 wk	5^{[44,58,61,66,68]}	0.97 (0.39, 1.54)	P < .0001	86	Random effects model	P = .001	P = .59	0
>2 wk	8^{[38,39,42,47,49,54,55,59]}	1.15 (0.79, 1.51)	P = .0002	76	Random effects model	P < .00001	P = .59	0

SMD = standardized mean difference.